| TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms. | neoplasm, |
| Data suggest that deregulated expression of TET2 by DNA hypermethylation may contribute to the aberrantly low level of 5hmC in parathyroid carcinoma and further that TET2 plays a cell growth and cell migratory regulatory role and may constitute a parathyroid tumor suppressor gene. | thyroid, |
| Data showed that TET2 was downregulated in glioblastoma multiforme (GBM) and was involved in miR-19a-mediated proliferation and metastasis by directly being targeted. Its ectopic overexpression remarkably abrogated the facilitative effect of miR-19a on GBM. These findings indicated that TET2 worked as an anti-oncogene in GBM. Also, the expression of TET2 was positively regulated by AC016405.3. | GBM,glioblastoma, |
| It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F | None |
| With diverse genetic methods, TET2 on chromosome 4q24 was identified as candidate tumor suppressor gene. | None |
| Tet2 functions as a tumor suppressor to maintain hematopoietic cell homeostasis. | None |
| TET2, a tumor suppressor in hematological disorders. | None |
| findings define a novel _phospho-switch_ that regulates TET2 stability and a regulatory pathway that links glucose and AMPK to TET2 and 5hmC, which connects diabetes to cancer; data also unravel an epigenetic pathway by which metformin mediates tumour suppression; thus, this study presents a new model for how a pernicious environment can directly reprogram the epigenome towards an oncogenic state | None |
| Data show that tet oncogene membrane 2 (TET2) is required for exit of the GC, B-cell differentiation, and is a tumor suppressor for mature B cells. | None |
| Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy | None |
| Low expression of tet oncogene family member 2 protein (TET2) in children with lymphoblastic leukemia, acute, childhood (ALL) is associated with poor prognosis and can be used as a molecular prognostic marker for risk group stratification. | leukemia, |
| Data indicate the cooperation between receptor tyrosine kinase KIT D816V mutation and loss of function of tet oncogene 2 (TET2) in mast cell transformation in systemic mastocytosis (SM). | None |
| Findings indicate a novel type of hematological malignancy induced by tet oncogene 2 protein (Tet2) loss. | None |
| Data indicate that tet oncogene family member 2 protein (TET2) mutations can identify patients more likely to respond to hypomethylating agents (HMAs). | None |
| Data show that tet oncogene family member 2 (TET2) cysteine-rich (CR) domain mutations disrupt the recognition of histone H3 lysine 36 (H3K36) methylation, its cellular localization, and enzyme activity. | None |
| Results indicate that tet oncogene 1 protein (Tet1) and tet oncogene 2 protein (Tet2) play a critical role in maintaining bone marrow MSCs (BMMSCs) and bone homeostasis through demethylation of P2X7 purinoceptor (P2rX7) to control exosome and miRNA release. | None |